This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Klinefelter syndrome, male with more than two X chromosomes클라인펠터증후군, 두 개 이상의 X염색체를 가진 남성

Contents and key information
ItemDetails
A. Classification codesICD-10: Q98.1 | Special Copayment Reduction: V218 | Re-certification interval: 5 years
B. SynonymsNone
C. Adult onsetOnset in adulthood possible, but diagnosis in childhood is common — 48,XXXY and 49,XXXXY have more severe intellectual disability and physical abnormalities, so they are often diagnosed in childhood. Mild cases are diagnosed during infertility evaluation in adulthood.
1. History48,XXXY first reported by Fraccaro et al. in 1960 → 49,XXXXY reported in the 1960s → correlation between increasing X number and phenotypic severity established in the 1970s → current research on molecular mechanisms.
2. CausesSuccessive nondisjunction in meiosis I and II (mostly of maternal origin). The more extra X chromosomes, the more nondisjunction events required. 48,XXXY: 2 nondisjunctions; 49,XXXXY: 3 nondisjunctions.
3. Genetics48,XXXY (two X inactivated, double overexpression of escape genes from 1) or 49,XXXXY (three X inactivated). Escape gene dosage increases with the number of X chromosomes → phenotypic severity proportional.
4. Epidemiology48,XXXY: about 1 in 50,000 male births. 49,XXXXY: about 1 in 85,000~100,000. Very rare diseases.
5. PathophysiologyDosage-dependent overexpression of X escape genes → neurodevelopmental abnormalities (intellectual disability), skeletal abnormalities (radioulnar synostosis, joint laxity), more severe hypogonadism.
6. SymptomsIntellectual disability (moderate~severe), severely delayed language development, small testes and azoospermia, radioulnar synostosis, joint laxity, distinctive facial features. Severity increases as X number increases.
7. SignsHypotonia, radioulnar synostosis (limited forearm rotation), short neck, midface hypoplasia, congenital heart malformations. EEG abnormalities (epilepsy). Joint hypermobility.
8. ScreeningPrenatal cfDNA (detection of XXY/XXXY). Karyotyping for neonatal hypotonia or multiple malformations. Cytogenetic testing for developmental delay or intellectual disability.
9. DiagnosisKaryotyping (confirmation of 48,XXXY or 49,XXXXY). Developmental assessment, brain MRI, echocardiography, skeletal radiography. Hormone panel.
10. TreatmentTestosterone replacement (pubertal induction). Early intervention programs (speech, occupational and physical therapy). Neurodevelopmental support. Epilepsy management. Cardiac surgery (if malformations present). Multidisciplinary team.
11. PrognosisWorse prognosis than 47,XXY. Long-term dependence due to severe intellectual disability in 49,XXXXY. Function can improve with early intervention. Infertility is permanent.
12. PreventionGenetic counseling, invasive prenatal diagnosis. Start early intervention programs immediately. Preventive monitoring for complications. Educational support planning.
13. References10 references (PMID / DOI)

1. History

Q98.1 (male with more than two X chromosomes, Klinefelter variant) is a rare sex chromosome excess syndrome distinct from 47,XXY (Q98.0). This category mainly includes 48,XXXY and 49,XXXXY, each with its own clinical characteristics.

In 1960, Fraccaro et al. first reported a patient with a 48,XXXY karyotype. In the same year, Carr et al. first described 49,XXXXY; these patients were characterized by severe intellectual disability, distinctive facial features, radioulnar synostosis and multiple congenital malformations, and were recognized as a syndrome clearly different from the existing 47,XXY Klinefelter syndrome. From the mid-1960s, as several authors including Centerwall and Benirschke collected patients with 49,XXXXY, systematic description of its clinical characteristics was achieved.

In the 1970s, the concept of 'dose-dependent phenotypic worsening' was established, in which the severity of intellectual disability, physical dysmorphism and hypogonadism increases as the number of extra X chromosomes increases. This was understood to be because the copy number of genes escaping X inactivation increases in proportion to the number of X chromosomes.

With advances in molecular genetics in the 1990s, escape genes were identified, and in the 2000s X chromosome inactivation patterns and escape gene maps were refined through array CGH and SNP arrays. 49,XXXXY now tends to be recognized as an independent clinical syndrome, and the recognition is spreading that it has a complex phenotype beyond that of a simple Klinefelter variant.

2. Causes

48,XXXY and 49,XXXXY arise from successive nondisjunction events during meiosis. 48,XXXY, with one more extra X chromosome, requires two nondisjunction events, and 49,XXXXY requires three.

In 48,XXXY, two nondisjunctions in maternal meiosis form an XXX egg, which becomes 48,XXXY when fertilized by a Y sperm. Alternatively, after one maternal nondisjunction (forming an XX egg), one additional nondisjunction in the father (forming an XY sperm) may occur before fertilization. The latter is a rare pathway. Most extra X chromosomes are of maternal origin.

49,XXXXY requires the most complex nondisjunction pathway. After nondisjunction in maternal meiosis I, an additional nondisjunction in meiosis II may form an XXXX egg, which can be fertilized by a Y sperm. Alternatively, an XXXX egg may be formed by three successive maternal nondisjunctions. Formation of cell lines by secondary nondisjunction during mitosis causes mosaic forms. There is evidence that advanced maternal age increases the risk of nondisjunction. These diseases occur sporadically and the recurrence risk is low.

3. Genetics

In 48,XXXY, two of the three X chromosomes are inactivated and only one remains active. However, genes escaping X inactivation can be expressed from all three copies, achieving a higher escape gene dosage than in 47,XXY. In 49,XXXXY, three of the four X chromosomes are inactivated. The increase in the copy number of escape genes with the number of X chromosomes is the key molecular mechanism of increasing phenotypic severity.

Looking specifically at the effects of increased dosage of the main escape genes: SHOX (PAR1) strengthens the tall stature effect as its copy number increases, while also contributing to proximal lower limb shortening (skeletal dysmorphism similar to radioulnar abnormalities). KDM5C (Xp11.22) is a histone demethylase important for neurodevelopment and cognitive function, and when overexpressed it causes intellectual disability by a mechanism similar to X-linked intellectual disability. NLGN4X (Xp22.3) is a postsynaptic membrane adhesion molecule associated with autism spectrum disorder and language disorders. PCDH11X is involved in neuronal development.

Since 2011, 49,XXXXY has sometimes been called an independent syndrome, and there is also a view that its phenotypic differences from 47,XXY include qualitatively different features rather than simply quantitative differences. There is one Y chromosome, which determines the male phenotype through the SRY gene, but gonadal development is suppressed more severely by the effects of excess X escape genes.

4. General epidemiology

The variants corresponding to Q98.1 are very rare diseases. The incidence of 48,XXXY is estimated at about 1 per 50,000 male births. 49,XXXXY is even rarer, reported at about 1 per 85,000~100,000 male births. As of the 2020s, only a few hundred confirmed cases of 49,XXXXY exist worldwide.

Because intellectual disability and physical abnormalities are marked in these diseases, unlike 47,XXY they are often diagnosed in childhood. However, owing to their rarity, large cohort studies are lacking even internationally, and diagnosis is sometimes delayed because of the variability of clinical symptoms. The time of diagnosis is often an average of 4~6 years of age in 48,XXXY and the neonatal~infant period in 49,XXXXY.

There are reports that the association with advanced maternal age is stronger in these diseases than in 47,XXY. The recurrence risk is low, but prenatal diagnosis is recommended if it occurred in a previous child. In Korea they are classified as Q98.1 with V218 Special Copayment Reduction applied, and because of the low incidence, Korean epidemiological data are limited.

5. Pathophysiology

The pathophysiology of Q98.1 is explained by a mechanism of 'dosage-dependent abnormal gene expression,' in which expression of genes escaping X inactivation increases in proportion to the number of extra X chromosomes, affecting multisystem development.

In terms of neurodevelopment, overexpression of X escape genes such as KDM5C, NLGN4X and PCDH11X causes abnormalities in synapse formation, neuronal migration and dendritic development. The severity of intellectual disability increases with X number: mild cognitive impairment in 47,XXY, mild~moderate intellectual disability in 48,XXXY (mean IQ 40~60), and moderate~severe intellectual disability in 49,XXXXY (mean IQ 20~60, median about 40).

SHOX overexpression is involved in the pathogenesis of skeletal abnormalities, but the radioulnar synostosis, joint laxity, flat feet, etc. observed in 49,XXXXY may be related, beyond simple SHOX overexpression, to dosage abnormalities of genes regulating bone formation during embryonic development (including Xp genes such as ARSE and ANOS1). Radioulnar synostosis limits rotational movement of the forearm, causing severe impairment in daily activities.

Hypogonadism is more severe than in 47,XXY, with more marked decline in Leydig and Sertoli cell function. Because the capacity for testosterone secretion is lower, male secondary sexual characteristics appear incompletely even after puberty. Azoospermia is observed in almost all patients, and the likelihood of success with testicular sperm extraction is also very low. Congenital heart malformations (patent ductus arteriosus, atrial septal defect, etc.) occur in about 15~20%.

6. Symptoms

The symptoms of Q98.1 also differ between 48,XXXY and 49,XXXXY, and both variants show a more severe clinical picture than 47,XXY. The description focuses on phenotypic worsening with increasing X number.

48,XXXY

Intellectual disability (mild~moderate, mean IQ 40~60) is prominent and clearly more severe than in 47,XXY. Both expressive and receptive language development are severely delayed. Small testes, azoospermia and hypogonadism are more marked than in 47,XXY, with lower testosterone levels. Gynecomastia is common. Tall stature is absent or less pronounced. Hypotonia is observed from infancy. Behavioral problems (temper tantrums, impulsivity), social immaturity and, in some, autism spectrum traits are reported.

49,XXXXY

It shows an even more severe clinical picture. It is characterized by intellectual disability (moderate~severe, mean IQ 20~60) and severe language developmental delay (very late language acquisition, with some relying on nonverbal communication). Radioulnar synostosis occurs in about 70~80%, making forearm rotation impossible or severely limited. Joint laxity (joint hypermobility) and flat feet are common. Distinctive facial features: midface hypoplasia, upslanting palpebral fissures, epicanthal folds, a broad nose and low-set ears. Hypotonia is prominent and causes feeding difficulties in infancy. Congenital heart malformations (patent ductus arteriosus, etc.) occur in about 15~20%. Epilepsy occurs in some. Microcephaly or skull abnormalities. Underdevelopment of the penis and testes. Short neck, genu varum or genu valgum.

7. Signs

The main signs that can be identified clinically in Q98.1 are described by system.

Neurological

Generalized hypotonia in infancy. Delayed developmental milestones (head control, sitting and walking all delayed). Severely delayed language milestones. On brain MRI, abnormal corpus callosum development, cortical malformations and ventricular enlargement are observed in some patients with 49,XXXXY. Abnormal electroencephalogram (EEG) findings (epileptiform discharges).

Skeletal

Radioulnar synostosis (proximal bony fusion of the radius and ulna on plain radiographs). Joint hypermobility (wrist, ankle, knee). Flat feet. Scoliosis. Short fifth finger (clinodactyly) or brachydactyly of the little finger. Pelvic dysplasia findings.

Cardiovascular

Congenital heart malformations (patent ductus arteriosus, atrial septal defect, ventricular septal defect) occur in about 15~20%. Abnormal echocardiographic findings.

Endocrine

Markedly elevated FSH, elevated LH, severely low serum total testosterone (mostly below the lower limit of normal). Small testes (adult testicular volume 1~4 mL by orchidometer). Incomplete pubertal progression. Gynecomastia.

Ophthalmology

Strabismus observed in about 30~50%. Refractive errors. Epicanthal folds (common in 49,XXXXY).

8. Screening

Because intellectual disability and physical abnormalities are marked in 48,XXXY and 49,XXXXY, early diagnosis is possible through various clinical pathways.

Prenatal screening

cfDNA (NIPT) is used to screen for sex chromosome numerical abnormalities, and 48,XXXY or 49,XXXXY can be suspected from an increased X chromosome signal. However, current cfDNA algorithms are optimized mainly for 47,XXY, so sensitivity for detecting 48,XXXY and 49,XXXXY may be lower. As confirmatory testing, karyotyping and array CGH after amniocentesis are needed. When signs of heart malformations, joint abnormalities or developmental delay are observed on fetal ultrasound, sex chromosome analysis is performed.

Neonatal and infant period

With the combination of generalized hypotonia, feeding difficulties, distinctive facial features and multiple congenital malformations (especially radioulnar synostosis and congenital heart malformations) in the neonatal period, karyotyping is requested immediately. 49,XXXXY is often diagnosed in the neonatal period because of distinctive facial features and hypotonia.

Developmental delay in childhood

Chromosome analysis is performed in boys with moderate or greater intellectual disability, severe language developmental delay and motor developmental delay. In particular, 49,XXXXY should be strongly suspected in boys with intellectual disability accompanied by radioulnar synostosis (limited forearm rotation).

9. Diagnosis

Confirmation is made by identifying 48,XXXY or 49,XXXXY on peripheral blood G-banding karyotyping. Karyotyping must analyze a sufficient number of cells (at least 30) to accurately count the number of X chromosomes.

Complementary tests: FISH (X and Y probes) to confirm the chromosome number in each cell. Array CGH or SNP array to exclude structural abnormalities and analyze X inactivation patterns. Developmental and cognitive assessment: standardized intelligence tests (Bayley, K-ABC, Stanford-Binet), language development assessment, occupational therapy assessment. Brain MRI (identification of structural abnormalities). Echocardiography (exclusion of congenital heart malformations). Skeletal radiography (radioulnar synostosis, joint abnormalities). Ophthalmic examination (strabismus, refractive errors). Hormone panel (FSH, LH, total testosterone, free testosterone, estradiol, AMH, inhibin B). Bone density (DEXA). Hearing tests.

10. Treatment

Treatment of Q98.1 shares the basic principles with 47,XXY, but additional intensive support for more severe intellectual disability and physical abnormalities is needed.

Testosterone replacement therapy

Testosterone replacement for hypogonadism is started from early puberty, as in 47,XXY. However, in these variants testicular function is lower, so higher replacement doses may be needed. Continued replacement in adulthood improves muscle mass, bone density, energy level and mood.

Early intervention programs

In the neonatal period or immediately upon diagnosis, speech therapy (promoting expressive and receptive language development, use of augmentative and alternative communication (AAC) devices), occupational therapy (fine motor skills, independence in daily activities), physical therapy (hypotonia, joint laxity, gait training) and special education (establishing an individualized education program, IEP) are started. The intensity and timing of early intervention have a decisive influence on the long-term level of function.

Orthopedic treatment

Radioulnar synostosis: conservative management in mild cases; surgical correction (osteotomy to change the fixed angle) is considered when functional limitation is severe. Flat feet: use of orthoses. Scoliosis: bracing or surgical treatment.

Treatment of heart malformations

When congenital heart malformations are present, surgical or interventional treatment is performed in consultation with pediatric cardiac surgery.

Behavioral and mental health support

Behavioral therapy and, when needed, medication for behavioral problems (impulsivity, temper tantrums) and anxiety/depression. ABA therapy for autism spectrum traits. Family support and parent education.

11. Prognosis

The prognosis of Q98.1 differs by variant and is generally worse than that of 47,XXY. Prognosis is determined mainly by the severity of intellectual disability, the presence of heart malformations and the quality of early intervention.

Patients with 48,XXXY have mild~moderate intellectual disability, and some independent living is possible, but there are considerable limitations in occupational and social function. Testosterone replacement and speech and learning therapy help improve quality of life. Infertility is permanent, and the likelihood of successful testicular sperm extraction is much lower than in 47,XXY.

Patients with 49,XXXXY have moderate~severe intellectual disability and need long-term dependent support. Independent living is mostly impossible. Radioulnar synostosis severely limits daily activities. However, through early intensive intervention programs, communication ability, self-care ability and quality of life can improve significantly. Early correction of heart malformations is important for survival and long-term cardiac function. Life expectancy depends on management of complications, and survival into adulthood is possible in the absence of serious heart malformations.

12. Prevention

Primary prevention of Q98.1 is difficult because meiotic nondisjunction occurs sporadically. Because advanced maternal age is a risk factor, awareness of it is helpful.

Genetic counseling and prenatal diagnosis

If Q98.1 was diagnosed in a previous pregnancy, invasive prenatal diagnosis (karyotyping + array CGH after amniocentesis or chorionic villus sampling) is recommended in the next pregnancy. cfDNA is an adjunctive screening tool, and confirmatory testing is performed if the sex chromosome signal is increased. In genetic counseling after prenatal diagnosis, the variability of the phenotype and the uncertainty of prognosis are fully explained.

Start early intervention immediately

Starting early intervention programs (speech, occupational and physical therapy) as soon as the diagnosis is made has the greatest influence on long-term functional prognosis. The earlier it is started, ideally in the neonatal period or early infancy, the more effective it is.

Monitoring for prevention of complications

Congenital heart malformations are detected and treated early, and functional assessment of skeletal abnormalities (radioulnar synostosis) is performed to determine the appropriate timing of surgery. Testosterone replacement prevents complications of hypogonadism (osteoporosis, metabolic syndrome). When epilepsy develops, immediate neurological management is provided.

13. References

  1. Tartaglia N, et al. 48,XXXY, 48,XXYY, and 49,XXXXY syndromes: not just variants of Klinefelter syndrome. Acta Paediatr. 2011;100(6):851-860. PMID: 21241358
  2. Linden MG, et al. 47,XXX, 47,XXY, and 47,XYY syndromes: a review. Am J Med Genet. 1995;55(3):295-313. PMID: 7753017
  3. Visootsak J, Graham JM Jr. Klinefelter syndrome and its variants: an update and review for the primary pediatrician. Clin Pediatr (Phila). 2006;45(4):305-316. PMID: 16708081
  4. Fraccaro M, et al. A child with 48 chromosomes. Lancet. 1960;1(7130):899-902. PMID: 13797483
  5. Sheridan MK, et al. Developmental outcome in 49,XXXXY syndrome. Dev Med Child Neurol. 1995;37(8):745-752. PMID: 7672471
  6. Tartaglia N, et al. The effects of sex chromosome aneuploidy on brain morphology. Ann N Y Acad Sci. 2008;1138:171-186. PMID: 18837896
  7. Groth KA, et al. Klinefelter syndrome — a clinical update. J Clin Endocrinol Metab. 2013;98(1):20-30. PMID: 23118429
  8. Gravholt CH, et al. Klinefelter syndrome: integrating genetics, neuropsychology, and endocrinology. Endocr Rev. 2018;39(4):389-423. DOI: 10.1210/er.2017-00212
  9. Samango-Sprouse CA, et al. New insights and potential therapeutic options for boys with 49,XXXXY syndrome. Am J Med Genet C Semin Med Genet. 2015;169(1):1-5. PMID: 25581462
  10. Nieschlag E, et al. Guidelines for diagnosis, treatment and follow-up of Klinefelter syndrome. Andrology. 2016;4(4):545-556. PMID: 26924680